Renal Insufficiency - Dose Adjustments
Various antiretroviral drugs are excreted primarily through the kidney and must be dose adjusted in the setting of renal insufficiency or hemodialysis.
Dosage recommendations for antiretroviral drugs in renal insufficiency |
Renal function (mL/min) |
CrCl > 50 |
CrCl 30-49 |
CrCl 10-29 |
CrCl < 10 |
NRTI/Nucleotides |
| zidovudine |
300mg BID |
300mg BID |
300mg BID |
100mg Q8H* |
| didanosine EC |
BW³ 60kg |
400mg QD |
200mg QD |
125mg QD |
125mg QD |
BW <60kg |
250mg QD |
125mg QD |
125mg QD |
Do not use EC |
| zalcitabine |
0.75mg TID |
0.75mg BID |
0.75mg BID |
0.75mg QD |
| stavudine |
BW³ 60kg |
40mg BID |
20mg BID |
20mg QD |
20mg QD |
BW <60kg |
30mg BID |
15mg BID |
15mg QD |
15mg QD |
| lamivudine |
300mg QD |
150mg QD |
100mg QD |
25-50mg QD** |
| emtricitibine |
200mg QD |
200mg Q48h |
200mg Q72h*** |
200mg Q96h**** |
| abacavir |
300mg BID |
300mg BID |
300mg BID |
300mg BID |
| tenofovir |
300mg QD |
300mg Q48h |
300mg Q72-96h |
300mg Q72h |
NNRTIs |
| nevirapine |
200mg BID |
Standard |
Standard |
Standard |
| delavirdine |
600mg BID |
Standard |
Standard |
Standard |
| efavirenz |
600mg QHS |
Standard |
Standard |
Standard |
Protease Inhibitors |
| saquinavir |
1200mg TID |
Standard |
Standard |
Standard |
| ritonavir |
600mg BID |
Standard |
Standard |
Standard |
| indinavir |
800mg Q8h |
Standard |
Standard |
Standard |
| nelfinavir |
1250mg BID |
Standard |
Standard |
Standard |
| fosamprenavir |
1400mg BID |
Standard |
Standard |
Standard |
| lopinavir/r |
400mg BID |
Standard |
Standard |
Standard |
| atazanavir |
400mg QD |
Standard |
Standard |
Standard |
| tipranavir |
500mg BID |
Standard |
Standard |
Standard |
BID = every 12 hours; QD = every 24 hours
* Definitive dosing of AZT has not been established
**Manufacturer suggests a loading dose of 150mg (x1) when CrCl < 30 mL/min; doses
up to 150mg QD in end stage renal disease were demonstrated safe and tolerable. 2
***CrCl 15-29
****CrCl < 15
References:
- Dosing information taken from manufacturer prescribing information
- Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis.
Antimicrob Agents Chemother 2002 Aug; 46(8):2387-92
*Adobe Acrobat Reader is required for viewing or printing PDFs. Acrobat Reader is available free of charge from the Adobe website at http://www.adobe.com/prodindex/acrobat/readstep.html
|